Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 3Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Tissue Adhesions 1Thrombocythemia, Essential 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Neutropenia 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Myoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Endocrine Neoplasia Type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Sodium Chloride × Clear all
NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
178 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡